Ces radiol. 2019, 73(4):226-230 | DOI: 10.55095/CesRadiol2019/033
Prostate cancer in active surveillanceCase report
- 1 Ústav radiodiagnostický FN, Ostrava
- 2 Urologická ambulance Sagena, Frýdek-Místek
In the case report, we present a case of a 54 years old man with proven low grade prostate cancer who opted for an active monitoring - active surveillance. We describe the development of the disease in 18 monts with progression - carcinoma transfer to a higher degree.
The patient is monitored according to the recommended schedule for active monitoring to control the levels of PSA, clinical endorectal digital examination and MRI. We present a process dissemination along the peripheral zone with the possible effect of repeated biopsies on the process dissemination.
Marginally, we discuss the issue of active surveillance and the ability of MR to detect cancer progression.
Keywords: prostate cancer, active monitoring, magnetic resonance imaging, rebiopsy
Accepted: November 15, 2019; Published: December 1, 2019 Show citation
References
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE, Group PS. 10-years outcomesafter monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15): 1415-1424. doi: 10.1056/NEJMoa1606220
Go to original source... 
Go to PubMed... - Ahmed HU, Brown LC, Kaplan R, Parker C, Emberton M. Diagnostic accuracy of the PROMIS study - Authors' reply. Lancet 2017; 390(10092): 362. doi: 10.1016/S0140-6736(17)31595-7 Go to original source... Go to PubMed...
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76(3): 340-351. doi: 10.1016/j.eururo.2019.02.033 Go to original source... Go to PubMed...
- Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol 2017; 71(4): 648-655. doi: 10.1016/j.eururo.2016.06.011 Go to original source... Go to PubMed...
- Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33(3): 272-277. doi: 10.1200/JCO.2014.55.1192 Go to original source... Go to PubMed...
- Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE. Radical prostatectomy or watchful waiting in prostate cancer - 29-years follow-up. N Engl J Med 2018; 379(24): 2319-2329. doi: 10.1056/NEJMoa1807801 Go to original source... Go to PubMed...
- Bill-Axelson A, Holmberg L, Garmo H. Radical surgery or watchful waiting in prostate cancer. Reply. N Engl J Med 2019; 380(11): 1084. doi: 10.1056/NEJMc1900410 Go to original source...
- Gaur S, Harmon S, Rosenblum L, Greer MD, Mehralivand S, Coskun M, Merino MJ, Wood BJ, Shih JH, Pinto PA, Choyke PL, Turkbey B. Can apparent diffusion coefficient values assist PI-RADS version 2 DWI scoring? A Correlation Study Usingthe PI-RADSv2 and International Society of Urological Pathology Systems. Am J Roentgenol 2018; 211(1): W33-W41. Go to original source... Go to PubMed...
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, Collaborators PSG. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378(19): 1767-1777. doi: 10.1056/NEJMoa1801993 Go to original source... Go to PubMed...
- Radtke JP, Kuru TH, Bonekamp D, Freitag MT, Wolf MB, Alt CD, et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for theselection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis 2016; 19: 283. Go to original source... Go to PubMed...
- Abdi H, Pourmalek F, Zargar H, Walshe T, Harris AC, Chang SD, Eddy C, So AI, Gleave ME, Machan L, Goldenberg SL, Black PC. Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer. Urology 2015; 85(2): 423-428. doi: 10.1016/j.urology.2014.09.060 Go to original source... Go to PubMed...
- EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.